T

TScan Therapeutics Inc
NASDAQ:TCRX

Watchlist Manager
TScan Therapeutics Inc
NASDAQ:TCRX
Watchlist
Price: 1.06 USD 1.92% Market Closed
Market Cap: 60.2m USD

Wall Street
Price Targets

TCRX Price Targets Summary
TScan Therapeutics Inc

Wall Street analysts forecast TCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TCRX is 6.46 USD with a low forecast of 3.03 USD and a high forecast of 12.6 USD.

Lowest
Price Target
3.03 USD
186% Upside
Average
Price Target
6.46 USD
509% Upside
Highest
Price Target
12.6 USD
1 089% Upside
TScan Therapeutics Inc Competitors:
Price Targets
IPH
Innate Pharma SA
223% Upside
300896
Imeik Technology Development Co Ltd
38% Upside
688331
RemeGen Co Ltd
18% Upside
ACE
Ascelia Pharma AB
157% Upside
397030
AprilBio Co Ltd
3% Downside
KNSA
Kiniksa Pharmaceuticals Ltd
33% Upside
ARQT
Arcutis Biotherapeutics Inc
11% Upside
MDGL
Madrigal Pharmaceuticals Inc
2% Upside

Revenue
Forecast

Revenue Estimate
TScan Therapeutics Inc

For the last 4 years the compound annual growth rate for TScan Therapeutics Inc's revenue is 27%. The projected CAGR for the next 4 years is 65%.

27%
Past Growth
65%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
TScan Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
TScan Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TCRX's stock price target?
Price Target
6.46 USD

According to Wall Street analysts, the average 1-year price target for TCRX is 6.46 USD with a low forecast of 3.03 USD and a high forecast of 12.6 USD.

What is TScan Therapeutics Inc's Revenue forecast?
Projected CAGR
65%

For the last 4 years the compound annual growth rate for TScan Therapeutics Inc's revenue is 27%. The projected CAGR for the next 4 years is 65%.

Back to Top